Infection in Immunocompromised Patients
Patients with weakened immune systems may be susceptible to infections that are uncommon or more severe in immunocompetent individuals. A targeted diagnostic approach is important because the range of possible pathogens may be broad.
Depending on the clinical situation, testing may include viral load testing, opportunistic pathogen testing, fungal investigations, mycobacterial testing, blood culture, and molecular pathogen detection, selected based on the specific type and degree of immunosuppression.
At National Path Lab (NPL), a comprehensive range of testing is available to support the evaluation of infection in immunocompromised patients, in coordination with treating specialists.
- Tests available
- 6
- Tests available
- Health package
- 1
- Health package
Tests Available at NPL
QUANTIFERON®-TB GOLD (QFT)/TB-IGRA (INTERFERON GAMMA RELEASE ASSAY)
SAMPLE BY SAT TO THU 3:00 PM REPORT ON NEXT DAY LATE EVENING
Rs. 5000
CULTURE AEROBIC BLOOD; INCLUDES ANTIBIOTIC SENSITIVITY IF INDICATED
SAMPLE DAILY BY 8:00 PM 1ST INTERIM REPORT: 3RD DAY, FINAL REPORT: 5TH DAY
Rs. 1600
CYTOMEGALOVIRUS (CMV) DNA, QUANTITATIVE PCR
SAMPLE BY TUE 8:00 AM REPORT ON NEXT DAY EVENING
Rs. 11500
EPSTEIN BARR VIRUS (EBV), QUANTITATIVE PCR
SAMPLE DAILY BY 8:00 PM REPORT AFTER 10 DAYS
Rs. 13000
OPPORTUNISTIC INFECTION PANEL BY AFB STAIN (CYCLOSPORA, ISOSPORA, CRYPTOSPORIDIUM, MICROSPORIDIUM)
SAMPLE DAILY BY 6:00 PM, REPORT ON NEXT DAY
Rs. 2000
CULTURE FUNGUS DOES NOT INCLUDE ANTI BIOTIC SENSITIVITY
SAMPLE DAILY BY 8:00 PM, REPORT AFTER 3-28 DAYS.
Rs. 2200
About Infection in Immunocompromised Patients
Causes & Risk Factors
Immunocompromise can arise from several underlying causes, each associated with somewhat different infection risk patterns:
• HIV/AIDS — particularly with advanced disease and low CD4 count, increases susceptibility to opportunistic infections.
• Chemotherapy — causes temporary but sometimes profound immunosuppression, particularly affecting white blood cell counts.
• Organ or stem cell transplantation — requires ongoing immunosuppressive medication to prevent rejection, which also increases infection susceptibility.
• Chronic corticosteroid use — particularly at higher doses or for prolonged periods.
• Primary immunodeficiency — inherited conditions affecting immune function from birth.
• Poorly controlled diabetes — associated with increased susceptibility to certain infections.
Symptoms & When to Test
Immunocompromised patients may present with infections differently than the general population — symptoms can be blunted, atypical, or the infection may be more severe than expected for the apparent trigger.
• Fever without an obvious source — warrants prompt evaluation in an immunocompromised patient
• Infections that are unusually severe, prolonged, or recurrent for the situation
• Symptoms from unusual or opportunistic pathogens not typically seen in patients with normal immune function
• Infection symptoms that may be blunted or atypical, since a weakened immune response can reduce the usual inflammatory signs
• Rapid progression of infection compared to what would be expected in an immunocompetent person
When Should You Consider Testing?
Immunocompromised patients generally warrant a lower threshold for testing and prompt evaluation with any new fever or infection symptom, given the broader range of possible pathogens and the potential for rapid progression.
Why Tests Are Combined
Because immunocompromised patients are susceptible to a wide range of typical and atypical pathogens simultaneously — including viral, fungal, mycobacterial, and unusual bacterial causes — a broader initial testing approach is often warranted compared to an immunocompetent patient with similar symptoms, where a more limited work-up might be sufficient.
The specific combination of tests is tailored to the type and degree of immunosuppression — for example, an HIV patient with a very low CD4 count faces a different range of likely opportunistic infections than a transplant recipient on specific immunosuppressive medications, so testing strategy reflects the specific clinical context rather than a one-size-fits-all panel.
Molecular pathogen detection is particularly valuable in this population because it can identify organisms that are slow-growing, difficult to culture, or present at low levels — all more likely scenarios in an immunocompromised host — allowing for more timely, targeted treatment.
Tests Available at NPL
Test Code | Test | Clinical Relevance |
OS343 | EPSTEIN BARR VIRUS (EBV), QUANTITATIVE PCR | Monitors specific viral infections relevant to the patient's immunocompromised state |
N0010 | CYTOMEGALOVIRUS (CMV) DNA, QUANTITATIVE PCR | Monitors specific viral infections relevant to the patient's immunocompromised state |
M0023 | OPPORTUNISTIC INFECTION PANEL BY AFB STAIN (CYCLOSPORA, ISOSPORA, CRYPTOSPORIDIUM, MICROSPORIDIUM) | Targets specific organisms known to cause infection primarily in immunocompromised individuals. |
M0020 | CULTURE FUNGUS DOES NOT INCLUDE ANTI BIOTIC SENSITIVITY | Evaluates for fungal infections, which occur more frequently and can be more severe in immunocompromised patients. |
I0129 | QUANTIFERON®-TB GOLD (QFT)/TB-IGRA (INTERFERON GAMMA RELEASE ASSAY) | Evaluates for tuberculosis and other mycobacterial infections, relevant given increased susceptibility in immunocompromised individuals. |
M0001 | CULTURE AEROBIC BLOOD; INCLUDES ANTIBIOTIC SENSITIVITY IF INDICATED | Identifies bacterial or fungal bloodstream infection. |
Most infectious-disease molecular tests and microbiological investigations do not require fasting. However, some blood tests ordered at the same time may have specific preparation requirements. Please follow the instructions provided by your doctor or NPL.
Home Sample Collection
Routine blood-based monitoring tests (such as viral load testing) for stable immunocompromised patients can often be arranged through NPL's standard home sample collection service — confirm with your treating specialist which tests are appropriate for home collection given your specific situation.
New fever or acute infection symptoms in an immunocompromised patient generally warrant prompt evaluation by your treating specialist or at a hospital, rather than routine home collection, given the potential for rapid progression and the broader diagnostic work-up often required.
More invasive sample collection (such as bronchoscopy for suspected fungal or unusual respiratory infection) requires a specialist procedure at a hospital or clinic.
NPL coordinates closely with treating specialists to ensure appropriate, timely testing for immunocompromised patients.
When to See a Doctor
• Any new fever, especially without an obvious source
• Infection symptoms that seem unusually severe or are not improving as expected
• New or unusual symptoms in a person with known immunocompromise
Known immunocompromise with any symptom you are unsure about — contact your care team promptly rather than waiting
Medical Disclaimer Laboratory tests support the evaluation of infection in immunocompromised patients but must be interpreted by a qualified specialist together with the patient's specific immune status and clinical presentation. This content is for general information only and is not a substitute for medical advice, diagnosis, or treatment. |
